Omapatrilat: Neurohormonal and pharmacodynamic profile when administered with furosemide

Pharmacodynamic effects of combination therapy with omapatrilat and furosem ide were evaluated. Two groups of 13 healthy subjects each received furosem ide 20 mg daily for 15 days coadministered with either placebo on days 6 to 15 or omapatrilat 10 mg on days 6 to 10 and 25 mc on days 11 to 15, In the omapatrilat group, urinary excretion of atrial natriuretic peptide increas ed, and greater blood pressure reductions were seen compared with placebo. Concomitant omapatrilat treatment did not affect the acute diuresis, notriu resis, and kaliuresis observed with chronic administration of furosemide. N either effective renal plasma flow nor glomerular filtration rate changed i n either treatment group. No clinically significant safety issues were obse rved. Daily coadministration of omapatrilat 10 or 25 mg with furosemide 20 mg does not affect the pharmacodynamics of furosemide at steady state. (C) 2001 the American College of Clinical Pharmacology.